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Abstract 
Elevated levels of inflammatory markers, such as C-reactive protein, are well documented in 
people with depression. Few studies have examined whether the association between 
inflammation and depression is symptom specific, and differs according to antidepressant 
treatment. Using data from the English Longitudinal Study of Ageing (N = 5 909), cross-
sectional analyses revealed a significant dose-response association between C-reactive 
protein and the symptoms of fatigue (P < 0.001), restless sleep (P = 0.03), low energy (P = 
0.02) and feeling depressed (P = 0.04), but not other symptoms. These associations were 
absent in users of anti-depressant medication. Our findings suggest the C-reactive protein-
depression association is symptom-specific and modified by antidepressant treatment. 
 
Keywords: C-reactive protein; depression; antidepressants.  
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1. Introduction 
Levels of inflammatory markers, such as C-reactive protein (CRP), are elevated in people 
with symptoms of depression, although this is not a universal observation (Valkanova et al., 
2013). In these studies, depression symptomology is commonly measured with an aggregate 
score of different symptoms which may mask symptom-specific effects (Valkanova et al., 
2013).   
 
Initial analyses into specific symptoms of depression found a significant association 
between CRP levels with an increased risk that participants reported they had “not 
accomplished much recently” and felt “like giving up”, but not “often feeling nervous or 
stressed” (Wium-Andersen et al., 2013). These analyses were not, however, mutually 
adjusted for other symptoms, so they could be attributed to either somatic (e.g., fatigue) or 
psychological symptoms (e.g., feelings of low self-worth). In a recent item-level analysis of 
the US National Health and Nutrition Examination Survey, investigators adjusted these 
associations for the effect of other depressive symptoms and found CRP was independently 
associated with somatic (e.g., reports of tiredness, lack of energy, sleep problems and lack 
of appetite) but not psychological symptoms of depression (e.g., reports of depressed mood, 
anhedonia, feelings of self-worth) (Jokela et al., 2016).  
 
We examined these relationships in the English Longitudinal Study of Ageing (ELSA), a 
population of older people in whom levels of inflammatory markers and the occurrence of 
depression tend to be higher. Additionally, given that antidepressant drug therapy can have 
an inflammation-lowering effect (Hannestad et al., 2011), we explore the link between 
inflammation and specific symptoms of depression according to the use of such medication.   
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2. Materials and methods 
2.1 Participants 
Initiated in 2002/03 when study members were 50 years of age or older, the ELSA is an on-
going, biennial, nationally representative, multi-disciplinary prospective cohort study of 
older people (Steptoe et al., 2013).  Ethical approval was given by the National Research 
Ethics Service (MREC/01/2/91) and written informed consent obtained from all 
participants.  
 
For the present analyses, we report on data collected at wave six (2012-2013), when blood 
samples for CRP and medication use were collected by nurses (Steptoe et al., 2013). A total 
of 10 601 participants attended the wave six assessment, with 4 476 excluded from our 
analysis owing to missing data on CRP, or incomplete data on depressive symptoms, 
medication use, or potential confounding or mediating factors (n=216), resulting in a final 
sample size of 5 909 (mean age, 66 years; 54.9% female). Missing values on CRP were due 
to exclusions placed on participants who had a clotting or bleeding disorder (e.g., 
haemophilia or low platelets), those who had ever had a fit or convulsion in the last five 
years, were currently taking anticoagulant drugs (e.g., warfarin), or were unwilling to give 
their consent in writing for the drawing of blood (Steptoe et al., 2013).   
 
2.2 C-reactive protein 
CRP was measured using standard procedures (median, 1.6 mg/L; interquartile range, 0.8-
3.2 mg/L) (Bridges et al., 2012) and analysed using the N Latex CRP mono Immunoassay 
on the Behring Nephelometer II Analyzer (Dade Behring, Milton Keynes, UK). As the 
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original (Shapiro-Wilk test: V = 2169.78, P<0.001) and log-transformed (V = 30.79, 
P<0.001) CRP data were originally skewed, we categorized values into quartiles.  
 
2.3 Depressive symptoms 
Depressive symptoms were assessed using the eight-item version of the Center for 
Epidemiological Studies-Depression scale (CES-D)  which has comparable psychometric 
properties to the full 20-item CES-D  (Turvey et al., 1999). Items captured information on 
whether or not participants had experienced different symptoms of depression, “much of the 
time” in the past week. Items were categorised according to a 3-factor solution (negative 
affect, anhedonia, somatic) identified in an analysis of CES-D data across five cohort 
studies (Carleton et al., 2013). We characterised items loading on negative affect and 
anhedonia factors as assessing psychological symptoms, resulting in three somatic 
symptoms (“everything I did was an effort”, “sleep was restless” and “I could not get 
going”) and five psychological symptoms (“enjoyed life”, “felt depressed”, “happy”, 
“lonely”, “felt sad”).  
 
2.4 Confounding variables 
Information on self-reported physician-diagnoses of autoimmune and inflammatory 
disorders were recorded (diabetes, rheumatoid arthritis, and coronary heart disease). The use 
of medications with an anti-inflammatory effect (glucocorticoids and beta blockers), 
antidepressants and body mass index (BMI) were assessed during a visit to participants’ 
homes by nurses. Antidepressants, glucocorticoids and beta blockers were categorized using 
the British National Formulary (BNF) 61 (“British National Formulary (BNF) 61 - March 
2011”). 
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2.5 Statistical analysis 
We used χ2 test to examine differences in categorical variables. Depressive symptoms were 
treated as dichotomous variables (no=0, yes=1). We examined associations between 
quartiles of CRP and individual CES-D items in separate logistic regression models in 
which effect estimates were adjusted for sex, age, and race/ethnicity, and the sum of the 
remaining items (to account for the overlap between different depressive symptoms), 
autoimmune and inflammatory disorders, glucocorticoids and beta blockers (model 1). We 
then additionally adjusted for BMI (model 2). We tested for a difference in the trend across 
quartiles of CRP using orthogonal polynomial contrasts. We then included an interaction 
term between quartiles of CRP and antidepressant treatment.  
 
A sensitivity analysis using linear regression examined the association between CRP with 
the sum of the three items assessing somatic symptoms, and also the sum of the five 
psychological symptoms. All analyses were conducted using Stata 13. 
 
3. Results 
3.1 Association between C-reactive protein and depressive symptoms 
After adjusting for autoimmune disorders, inflammatory disorders, and anti-inflammatory 
medication there was an independent, dose-response association between quartiles of CRP 
and somatic symptoms relating to everything being an effort (odds ratios [ORs] of 1.20, 
1.31, and 1.97 for the second, third, and fourth quartiles of CRP respectively, compared with 
the first; P for trend <0.001), restless sleep (ORs of 1.11, 1.15, and 1.37; P for trend = 
0.002), and not being able to get going (ORs of 1.33, 1.40, and 1.60; P for trend = 0.007). 
The association with negative affect (“felt depressed”) was also statistically significant (P 
for trend   = 0.03); but for other items relating to affect (sadness) and anhedonia were not 
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(Tables 1 and 2). Additional adjustment for BMI partially attenuated estimates for restless 
sleep (ORs of 1.08, 1.11, and 1.30; P for trend = 0.002) and not being able to get going 
(ORs of 1.28, 1.31, and 1.45; P for trend = 0.02). 
 
3.2 Association between C-reactive protein and depressive symptoms stratified by 
antidepressant use 
For the one in ten participants who took antidepressants (10.6 %), the association between 
CRP and all but the symptoms of restless sleep (model 1: P = 0.03; model 2: P = 0.04) and 
feeling depressed (P = 0.02) were not significant at conventional levels (model 1: Tables S1 
and S2). In contrast, among study members not treated with antidepressants, there was an 
independent dose-response association for somatic symptoms (Table S3). The associations 
between CRP and restless sleep (P = 0.16) and not being able to get going (P = 0.12) were 
attenuated after adjustment for BMI, whereas the association for everything being an effort 
was not (P <0.001).  
 
There was a non-significant association between quartiles of CRP and psychological 
symptoms among those untreated with antidepressants (Table S3), and an inverse 
association between CRP and feeling depressed (P = 0.02). A significant interaction 
indicated the dose-response trend was stronger in those untreated than treated with 
antidepressants for the items relating to fatigue/ low motivation - everything being an effort 
(P for a difference in trend = 0.02) and restless sleep (P for a difference in trend = 0.04, see 
Supplementary Fig. 1). 
 
3.3 Sensitivity analyses 
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People with missing data had fewer symptoms of depression (P<0.001), except restless 
sleep (P=0.09); fewer reported baseline heart disease (P = 0.005), diabetes, rheumatoid 
arthritis and used antidepressants (P<0.001); they had a lower body mass index and level of 
CRP (P<0.001), more took beta blockers (P = 0.03), but no differences were found by age, 
sex, or the use of glucocorticoids (P>0.05). The pattern of attenuation for our main results 
was replicated in models using the sum of the items assessing somatic (Tables S5) or 
psychological symptoms (Tables S6). 
 
4. Discussion 
We replicated the association between circulating CRP levels and the somatic symptoms of 
fatigue, restless sleep, and low levels of energy, in a representative community-based cohort 
of older adults. Importantly, we only found this association to be present in individuals who 
did not take antidepressants. This suggests that antidepressants modify the association 
between CRP and the somatic symptoms of depression, in particular symptoms related to 
fatigue and low motivation.  
 
The graded association between CRP with restless sleep, fatigue and low motivation was 
partially explained by differences in BMI. This pattern of attenuation replicates that found in 
previous studies of CRP and the treatment for depression in elderly men (Almeida et al., 
2007) and depressive symptoms on the Patient Health Questionnaire in US Army soldiers 
(Douglas et al., 2004). Our results extend these findings to suggest that the attenuation by 
BMI may be more relevant for somatic than psychological symptoms. This attenuation 
could be due to confounding, whereby BMI increases levels of CRP and somatic depressive 
symptoms. However, it is also possible that BMI mediates the influence of CRP on somatic 
depressive symptoms, or that BMI influences CRP levels which, in turn, induce depressive 
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symptoms. No attenuation was found for the CES-D item on “everything they did was an 
effort” suggesting that this symptom is linked to CRP independently of the effects of BMI.   
 
Antidepressant use appeared to modify the association between CRP and somatic 
symptoms. Antidepressants may exert part of their effect through inhibition of inflammatory 
pathways (Hannestad et al., 2011), which is consistent with a meta-analysis showing 
inflammation is reduced after antidepressant treatment among people with depression 
(O’Brien et al., 2006), and two clinical trials showing decreases in interleukin-6 (Abbasi et 
al., 2012) and CRP (Raison et al., 2013) were associated with the treatment response from 
antidepressants.  
 
Our study has a number of strengths. It is the first study to examine the association between 
specific symptoms of depression and CRP according to antidepressant use. That the pattern 
of results we found closely replicates those from a US-based, younger cohort (US NHANES 
mean age = 48 years) (Jokela et al., 2016) and two population-based Danish studies (Wium-
Andersen et al., 2013), with different measures of depressive symptoms, supports the 
generalizability of our findings. The main limitation of this study is loss to follow-up, a 
perennial problem in longitudinal studies. The eligibility criteria placed on participants to 
provide a blood sample means those included may have been healthier than the overall 
cohort. The smaller number of antidepressant users meant we had less power in analyses for 
users than non-users. In addition, the possibility of survivor bias is a concern with any study 
of aging, where fewer unhealthy participants with high levels of CRP are available for 
analysis, such that the association with depressive symptoms might be underestimated. To 
  
10 
 
influence the pattern of results we found, this bias would, however, have to operate 
systematically according to antidepressant use.   
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Table 1. Association between Quartiles of C-reactive Protein and ‘Somatic’ Depression Symptoms in the ELSA cohort (N = 5909)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Model 1 adjusted for age, sex, race/ethnicity, and the sum of all the other depression symptoms besides the outcome symptom, autoimmune and 
inflammatory disorders: diabetes, rheumatoid arthritis and heart disease; glucocorticoids and beta blockers. Glucocorticoids comprised of Prednisolone, 
Hydrocortisone, Deltacortril, and Budesonide. Beta blockers comprised of Atenolol, Bisoprolol, Metoprolol, Propranolol Hydrochloride, and Labetalol 
Hydrochloride 
b Model 2 comprised model 1 plus body mass index.  
 
 
 
 OR (95% CI) a b  
Outcome C-reactive protein (mg/L) 
Symptomatic, 
% (N)  
Model 1  Model 2  
Everything they did was an effort 0.10 to 0.79 11.6 (190) 1.00 (reference) 1.00 (reference) 
 0.80 to 1.60 14.9 (215) 1.20 (0.95, 1.52) 1.20 (0.94, 1.53) 
 1.61 to 3.30 16.2 (230) 1.31 (1.03, 1.65) 1.31 (1.03, 1.66) 
 3.31 to 157.50 24.4 (342) 1.97 (1.58, 2.47) 1.97 (1.56, 2.50) 
P-trend 
  <0.001 <0.001 
Sleep was restless  0.10 to 0.79 29.5 (485) 1.00 (reference) 1.00 (reference) 
 0.80 to 1.60 32.6 (471) 1.11 (0.94, 1.30) 1.08 (0.91, 1.28) 
 1.61 to 3.30 33.8 (480) 1.15 (0.98, 1.35) 1.11 (0.94, 1.31) 
 3.31 to 157.50 40.4 (566) 1.37 (1.16, 1.60) 1.30 (1.09, 1.54) 
P-trend 
  0.002 0.03 
Could not get going much of the time 0.10 to 0.79 11.6 (190) 1.00 (reference) 1.00 (reference) 
 0.80 to 1.60 15.6 (226) 1.33 (1.06, 1.68) 1.28 (1.01, 1.62) 
 1.61 to 3.30 16.7 (238) 1.40 (1.11, 1.76) 1.31 (1.03, 1.66) 
 3.31 to 157.50 21.9 (307) 1.60 (1.27, 1.99) 1.45 (1.14, 1.84) 
P-trend 
  0.007 0.02 
  
Table 2. Association between Quartiles of C-reactive Protein and ‘Psychological’ Depression Symptoms in the ELSA cohort (N = 5909) 
   OR (95% CI) a b 
Outcome C-reactive protein (mg/L) 
Symptomatic, 
% (N)  Model  1
 
 Model 2   
Felt depressed much of the time 0.10 to 0.79 8.4 (138) 1.00 (reference) 1.00 (reference) 
 0.80 to 1.60 12.0 (174) 1.45 (1.11, 1.88) 1.44 (1.11, 1.88) 
 1.61 to 3.30 11.8 (168) 1.37 (1.05, 1.78) 1.36 (1.03, 1.78) 
 3.31 to 157.50 14.1 (197) 1.24 (0.96, 1.62) 1.23 (0.93, 1.63) 
P-trend   0.03 0.04 
Happy much of the time 0.10 to 0.79 91.5 (1502) 1.00 (reference) 1.00 (reference) 
 0.80 to 1.60 90.5 (1309) 1.02 (0.77, 1.34) 0.98 (0.74, 1.29) 
 1.61 to 3.30 90.9 (1290) 1.07 (0.81, 1.41) 1.00 (0.75, 1.33) 
 3.31 to 157.50 89.1 (1248) 1.16 (0.88, 1.53) 1.05 (0.78, 1.41) 
P-trend   0.72 0.96 
Lonely much of the time 0.10 to 0.79 9.1 (149) 1.00 (reference) 1.00 (reference) 
 0.80 to 1.60 9.3 (135) 0.89 (0.70, 1.16) 0.89 (0.69, 1.16) 
 1.61 to 3.30 10.2 (144) 0.92 (0.72, 1.19) 0.94 (0.72, 1.22) 
 3.31 to 157.50 13.6 (190) 1.05 (0.82, 1.34) 1.07 (0.82, 1.39) 
P-trend   0.56 0.53 
Enjoyed life much of the time 0.10 to 0.79 92.8 (1524) 1.00 (reference) 1.00 (reference) 
 0.80 to 1.60 91.9 (1330) 1.03 (0.77, 1.39) 0.97 (0.72, 1.31) 
 1.61 to 3.30 90.8 (1288) 0.87 (0.66, 1.16) 0.78 (0.58, 1.05) 
 3.31 to 157.50 89.8 (1258) 1.05 (0.79, 1.41) 0.90 (0.66, 1.22) 
P-trend   0.57 0.36 
Felt sad much of the time 0.10 to 0.79 15.8 (259) 1.00 (reference) 1.00 (reference) 
 0.80 to 1.60 17.1 (248) 0.99 (0.81, 1.22) 1.00 (0.81, 1.23) 
 1.61 to 3.30 16.2 (230) 0.87 (0.70, 1.07) 0.87 (0.70, 1.08) 
 3.31 to 157.50 19.1 (267) 0.83 (0.67, 1.03) 0.83 (0.66, 1.04) 
P-trend   0.22 0.27 
  
a
 Model 1 adjusted for age, sex, race/ethnicity, and the sum of all the other depression symptoms besides the outcome symptom, autoimmune and 
inflammatory disorders: diabetes, rheumatoid arthritis and heart disease; glucocorticoids and beta blockers. Glucocorticoids comprised of Prednisolone, 
Hydrocortisone, Deltacortril, and Budesonide. Beta blockers comprised of Atenolol, Bisoprolol, Metoprolol, Propranolol Hydrochloride, and Labetalol 
Hydrochloride 
b Model 2 comprised model 1 plus body mass index.  
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Highlights 
• The association between C-reactive protein and depressive symptoms may be 
symptom specific. 
• We found a dose-response association between C-reactive protein and symptoms of 
fatigue, restless sleep, and low energy, but not psychologically orientated symptoms. 
• The inflammation-depression association was modified by antidepressant treatment, 
such that associations were only found in people untreated. 
 
